Abstract
Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Current Drug Targets
Title: Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Volume: 10 Issue: 10
Author(s): Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles and Monica M. Mita
Affiliation:
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Abstract: Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, Mita Alain, Sankhala Kamalesh, Swords Ronan, Kelly Kevin, Giles Francis and Mita M. Monica, Targeting Sarcomas: Novel Biological Agents and Future Perspectives, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577990
DOI https://dx.doi.org/10.2174/138945009789577990 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Virus-based Gene Transfer Approaches and Adipose Tissue Biology
Current Gene Therapy Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Myocardial Regeneration: What is the Best Approach?
Current Cardiology Reviews Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy Medullary Thyroid Cancer: A Promising Model for Targeted Therapy
Current Molecular Medicine CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry The MYCN Oncogene as a Specific and Selective Drug Target for Peripheral and Central Nervous System Tumors
Current Cancer Drug Targets The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine